GlassScriptPhysician profile
Christopher Vreeland
NPI 1801877469
$17,269.64
in general payments reported to CMS, 2019-2025
46 companies · $4,365 in 2025
The $4,365 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,456 · 2022: $2,802 · 2023: $4,666 · 2024: $3,980 · 2025: $4,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,348 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,640 · Travel and Lodging: $1,523 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,348.39 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,640.00 |
| Travel and Lodging | $1,522.66 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Senseonics, Incorporated | $3,440.00 | 2022-2025 | Eversense |
| Medtronic, INC. | $2,337.39 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Minimed 770g |
| Novo Nordisk INC | $1,660.71 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $1,139.75 | 2021-2025 | Freestyle Libre 3 |
| Mannkind Corporation | $981.01 | 2021-2025 | Afrezza |
| Beta Bionics, INC. | $777.48 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Bigfoot Biomedical INC | $701.27 | 2022-2023 | Unity Diabetes Management System |
| Novartis Pharmaceuticals Corporation | $593.02 | 2022-2025 | |
| Dexcom, INC. | $586.85 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $537.54 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $479.69 | 2021-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $441.34 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $439.29 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Cequr Corporation | $362.20 | 2022-2025 | Cequr Simplicity |
| Amgen INC. | $327.34 | 2023-2025 | Repatha, Evenity, Prolia |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $247.45 | 2022-2023 | |
| Sequel Med Tech, LLC | $226.65 | 2025 | Twiist |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.29 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Ibsa Pharma INC. | $218.06 | 2021-2025 | Tirosint, Licart, Licart |
| Abbvie INC. | $166.17 | 2021-2023 | |
| Tandem Diabetes Care, INC. | $157.70 | 2022-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Zealand Pharma US, INC. | $135.97 | 2021-2022 | |
| Insulet Corporation | $133.81 | 2021-2025 | Omnipod |
| Amneal Pharmaceuticals LLC | $132.27 | 2021-2025 | Unithroid |
| Astrazeneca Pharmaceuticals LP | $95.18 | 2022-2023 | Farxiga |
| Grt US Holding, INC. | $94.94 | 2021-2022 | |
| Radius Health, INC. | $77.11 | 2021-2024 | Tymlos |
| Madrigal Pharmaceuticals | $60.20 | 2024-2025 | Rezdiffra, Resmetirom |
| Esperion Therapeutics, INC. | $50.60 | 2021-2024 | Nexletol |
| Lifescan, INC. | $46.90 | 2021-2022 | |
| Astellas Pharma US INC | $43.41 | 2024-2025 | Veozah |
| Embecta Corp. | $40.33 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Bayer Healthcare Pharmaceuticals INC. | $35.07 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $31.54 | 2021-2023 | Strensiq |
| Merck Sharp & Dohme LLC | $28.87 | 2021-2022 | |
| Becton, Dickinson and Company | $25.28 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.94 | 2023 | Cycloset |
| Genentech USA, INC. | $21.78 | 2023 | Vabysmo |
| Azurity Pharmaceuticals, INC. | $20.90 | 2023 | Adthyza |
| Amphastar Pharmaceuticals, INC. | $20.72 | 2024 | |
| Horizon Therapeutics Plc | $20.31 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $19.98 | 2021 | |
| Ascendis Pharma Endocrinology INC | $18.57 | 2025 | Yorvipath |
| Recordati_rare_diseases_inc. | $16.46 | 2025 | Isturisa |
| Kyowa Kirin, INC. | $16.42 | 2024 | Crysvita |
| Tolmar, INC. | $13.88 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Vreeland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.